Effects of Spermidine-Rich Rice Germ Extract Supplement on Biomarkers of Healthy Aging and Autophagy-Proof-of-Concept Pilot Study.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

The study aimed to examine the effects of spermidine from Miricell™ rice germ extract (Nutraland USA) on biomarkers/indices of autophagy, neuroprotection, and cardiometabolic health, as well as safety and adverse events.

Why It Was Studied

Spermidine, autophagy, beclin-1, ULK1, rice germ extract, neuroprotection, BDNF, homocysteine, cardiometabolic, CRP, C-reactive protein, VLDL, triglycerides, aging.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Twelve (N=12) healthy men and women (age: 54.5 ± 7.9 years).

How the Study Was Run

In design terms this was a randomized, single-blind, parallel-group and pilot study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Only one side, usually the participants, was kept unaware of whether Copper (Supplement) was given.

The Copper (Supplement) group and the comparison group ran side by side rather than switching.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

This 56-day study was conducted as a single-blinded, interventional, parallel-group, pilot trial.

Vitals, diet records, and protocol compliance were recorded at weeks 0 and 8.

Blood draws for cardiometabolic markers and adverse event monitoring took place at screening and weeks 0 and 8.

Conducted at a clinical research laboratory in Ohio.

What Was Measured

Topics PubMed links to this paper include Pilot Projects, Spermidine, Biomarkers, Autophagy, Oryza, Plant Extracts and Healthy Aging.

What This Means in Plain Language

The paper is a randomized, single-blind and parallel-group study of Copper (Supplement).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Alternative therapies in health and medicine), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.